New Silk Route to invest in Indian drug company

Nectar Lifesciences has received board approval to issue up to 26m equity shares to the private equity firm.

5 January 2013•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.